WESTLAKE VILLAGE BIOPARTNERS
Westlake Village BioPartners is a venture capital firm focused on incubating and building life sciences companies with entrepreneurs that have the potential to bring transformative therapies and technologies to patients. The Westlake model is built on the founding team’s unique experience in successfully identifying and developing breakthrough therapies and building organizations.
WESTLAKE VILLAGE BIOPARTNERS
Industry:
Business Development Financial Services Venture Capital
Founded:
2018-01-01
Status:
Active
Contact:
(888) 828-6713
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Content Delivery Network
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-09-06 | ArsenalBio | Westlake Village BioPartners investment in Series B - ArsenalBio | 220 M USD |
| 2022-08-25 | 3T Biosciences | Westlake Village BioPartners investment in Series A - 3T Biosciences | 40 M USD |
| 2022-05-23 | Sinogen Biopharma | Westlake Village BioPartners investment in Series A - Sinogen Biopharma | 10 M USD |
| 2022-03-30 | Neuron23 | Westlake Village BioPartners investment in Series C - Neuron23 | 100 M USD |
| 2022-02-16 | Electra Therapeutics | Westlake Village BioPartners investment in Series B - Electra Therapeutics | 84 M USD |
| 2022-02-16 | Star Therapeutics | Westlake Village BioPartners investment in Venture Round - Star Therapeutics | 100 M USD |
| 2022-01-26 | Kyverna Therapeutics | Westlake Village BioPartners investment in Series B - Kyverna Therapeutics | 85 M USD |
| 2021-11-16 | ACELYRIN | Westlake Village BioPartners investment in Series B - ACELYRIN | 250 M USD |
| 2021-11-15 | Recludix Pharma | Westlake Village BioPartners investment in Series A - Recludix Pharma | 60 M USD |
| 2021-09-29 | Expansion Therapeutics | Westlake Village BioPartners investment in Series B - Expansion Therapeutics | 80 M USD |